Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
November 04, 2024 07:30 ET
|
Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
September 30, 2024 07:30 ET
|
Angitia Incorporated Limited
WOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024
September 16, 2024 07:30 ET
|
Angitia Biopharmaceuticals
Angitia announces multiple presentations at ASBMR.